Did Serendipity Contribute to the Discovery of New Antidepressant Drugs? Historical Analysis Using Operational Criteria

dc.contributor.authorLópez Muñoz, Francisco
dc.contributor.authorD’Ocón, Pilar
dc.contributor.authorRomero Martínez, Manuel Alejandro
dc.contributor.authorDe Berardis, Domenico
dc.contributor.authorÁlamo, Cecilio
dc.date.accessioned2025-05-22T18:00:41Z
dc.date.available2025-05-22T18:00:41Z
dc.date.issued2025
dc.descriptionAuthor Contributions Conception–FL-M; Design–FL-M; Supervision–FL-M, PD’O, AR, DDB, CÁ; Materials–FL-M; Data Collection and/or Processing–FL-M; Analysis and/or Interpretation–FL-M, PD’O, AR, DDB, CÁ; Literature Review–FL-M; Writing–FL-M; Critical Review–FL-M, PD’O, AR, DDB, CÁ. All authors read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work
dc.description.abstractObjective: Given their great importance, as one of the most prescribed types of therapeutic drugs worldwide, we have analyzed the role of serendipity in the discovery of new antidepressants, ranging from selective serotonin reuptake inhibitors to more contemporary developments. Methods: We carried out a historical analysis of the discovery of new antidepressants, resorting to the original articles published on their development (initial pharmacological and clinical information) and applied an operational criterion of serendipity developed by our group. Results: Selective serotonin reuptake inhibitors (fluoxetine, fluvoxamine, citalopram, paroxetine, sertraline, and escitalopram), selective dopamine and noradrenaline reuptake inhibitors (bupropion), noradrenaline and serotonin reuptake inhibitors (venlafaxine, milnacipram, duloxetine, and desvenlafaxine), selective noradrenaline reuptake inhibitors (reboxetine), noradrenergic and specific serotonergic antidepressants (mirtazapine), melatonergic agonists (agomelatine), and serotonin modulators and stimulators (vortioxetine, vilazodone, tianeptine) correspond to the type IV pattern. Moclobemide, a reversible monoamine oxidase inhibitor, corresponds to the type II pattern, for which the initial serendipitous findings (i.e., the chance discovery of the inhibitory effects of monoamine oxidase (MAO) whilst being studied for their antihyperlipidemic properties) led to subsequent non-serendipitous discoveries (clinical antidepressant efficacy). Ketamine, a glutamatergic modulator, corresponds to the type III pattern, characterized by a non-serendipitous origin (initial development as an anesthetic agent) leading to a serendipitous observation (the discovery of antidepressant efficacy in individuals illicitly using). Conclusion: The majority of new antidepressants adhere to a type IV pattern, characterized by a rational and targeted design process where serendipity played no part, except moclobemide (type II pattern) and ketamine (type III pattern)
dc.description.departmentDepto. de Farmacología y Toxicología
dc.description.facultyFac. de Veterinaria
dc.description.refereedTRUE
dc.description.statuspub
dc.identifier.citationLópez-Muñoz, F., D'Ocón, P., Romero, A., De Berardis, D., & Álamo, C. (2025). Did Serendipity Contribute to the Discovery of New Antidepressant Drugs? Historical Analysis Using Operational Criteria. Alpha psychiatry, 26(2), 40037. https://doi.org/10.31083/AP40037
dc.identifier.doi10.31083/AP40037
dc.identifier.essn2757-8038
dc.identifier.officialurlhttps://doi.org/10.31083/AP40037
dc.identifier.pmid40352067
dc.identifier.urihttps://hdl.handle.net/20.500.14352/120429
dc.issue.number2
dc.journal.titleAlpha Psychiatry
dc.language.isoeng
dc.page.final11
dc.page.initial1
dc.publisherIMR Press
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.cdu615.214
dc.subject.keywordAntidepressants
dc.subject.keywordHistory of medicine
dc.subject.keywordPsychopharmacology
dc.subject.keywordSerendipity
dc.subject.ucmPsicofarmacología
dc.subject.unesco3209.09 Psicofarmacología
dc.titleDid Serendipity Contribute to the Discovery of New Antidepressant Drugs? Historical Analysis Using Operational Criteria
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number26
dspace.entity.typePublication
relation.isAuthorOfPublicationc658be58-bda9-4100-ad65-bac31e1256af
relation.isAuthorOfPublication.latestForDiscoveryc658be58-bda9-4100-ad65-bac31e1256af

Download

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Did Serendipty.pdf
Size:
2 MB
Format:
Adobe Portable Document Format

Collections